NGGT recently shared promising new data regarding NGGT002, their gene therapy candidate currently in clinical trials for addressing Phenylketonuria (PKU).

Theragent and CellVax Therapeutics have reported the initial dosing of a patient in their Phase 2 study of FK-PC101, a new personalized cancer immunotherapy.

Allogene Therapeutics shared promising Phase 1 results showcasing ALLO-316's potential in advanced renal cell carcinoma patients at SITC and IKCS.

Fate Therapeutics Shares Preclinical Data on FT836, a MICA/B-targeted CAR T-cell, at 2024 SITC Meeting.

Myeloid Therapeutics to Present on MT-303, a Pioneering mRNA CAR Targeting GPC3 in Advanced HCC, at SITC 2024.

OncoResponse Reports Phase 1 Findings of OR502, an anti-LILRB2 Antibody, in Patients with Advanced Cancer.

Harbour BioMed has filed an IND application for HBM9378/SKB378 to treat chronic obstructive pulmonary disease.

SystImmune, Inc. has received FDA approval for the IND application of BL-M17D1 targeting advanced solid tumors.

Nammi Therapeutics, Inc. has reported the first patient has received QXL138AM in a Phase 1 trial focused on advanced solid tumors and multiple myeloma.

Pheast Shares Latest Preclinical Findings on PHST001, an Anti-CD24 Checkpoint Inhibitor for Macrophages, at SITC 2024.

Radella Pharmaceuticals reveals preliminary results from the Phase 1a trial of MD-18, a groundbreaking peptide aimed at PTP1B to combat obesity.

TEZSPIRE achieved its two main goals in the Phase III WAYPOINT study involving patients with chronic rhinosinusitis and nasal polyps.